British Columbia’s HIV Patient Safety Initiative is launched

  • British Columbia’s HIV Patient Safety Initiative is launched.
  • Funded by the Canadian Patient Safety Institute, this demonstration project developed a population-based surveillance system to monitor antiretroviral-related adverse events, and would later become BC-CfE’s Pharamcovigilance Initiative

Click here to learn more about adverse drug reaction reporting

Leave a Reply

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below